2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Sell
27
LPTX Quote, Financials, Valuation and Earnings
Last price:
$0.37
Seasonality move
:
-6.71%
Day range:
$0.36 - $0.40
52-week range:
$0.22 - $4.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.26x
P/B ratio:
0.75x
Volume:
268.2K
Avg. volume:
340.4K
1-year change:
-83.98%
Market cap:
$15.7M
Revenue:
--
EPS (TTM):
-$1.70
Analysts' Opinion
-
Consensus RatingLeap Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.00, Leap Therapeutics has an estimated upside of 693.65% from its current price of $0.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $0.38.
Fair Value
-
According to the consensus of 1 analyst, Leap Therapeutics has 693.65% upside to fair value with a price target of $3.00 per share.
LPTX vs. S&P 500
-
Over the past 5 trading days, Leap Therapeutics has overperformed the S&P 500 by 0.49% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Leap Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Leap Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Leap Therapeutics reported revenues of --.
Earnings Growth
-
Leap Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Leap Therapeutics reported earnings per share of -$0.37.
Enterprise value:
-17M
EV / Invested capital:
--
Price / LTM sales:
10.26x
EV / EBIT:
--
EV / Revenue:
-11.37x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.29x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$86.6M | -$58.1M | -$71.3M | -$14.6M | -$15.9M | |
| EBITDA | -$86.4M | -$57.3M | -$70.9M | -$13.8M | -$15.4M | |
| Diluted EPS | -$7.17 | -$2.13 | -$1.70 | -$0.51 | -$0.37 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $43.8M | $104.9M | $104.7M | $56.2M | $33.9M | |
| Total Assets | $45.8M | $105.9M | $106.5M | $58M | $34.9M | |
| Current Liabilities | $7.4M | $7.3M | $10.3M | $10.4M | $14M | |
| Total Liabilities | $7.4M | $7.3M | $78.2M | $10.6M | $14M | |
| Total Equity | $38.4M | $98.6M | $28.3M | $47.4M | $20.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$50.2M | -$46.6M | -$59.3M | -$15.5M | -$14.5M | |
| Cash From Investing | $49.3M | -$348K | -- | -- | -- | |
| Cash From Financing | -$29K | $28K | $37.1M | $29K | -$61K | |
| Free Cash Flow | -$50.2M | -$46.6M | -$59.3M | -$15.5M | -$14.5M | |
LPTX
Sector
Market Cap
$15.7M
$34.1M
Price % of 52-Week High
7.89%
45.43%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-83.98%
-39.29%
Beta (5-Year)
-0.167
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.37
200-day SMA
Sell
Level
$1.83
Bollinger Bands (100)
Sell
Level
-0.1 - 1.6
Chaikin Money Flow
Sell
Level
-93.4M
20-day SMA
Sell
Level
$0.38
Relative Strength Index (RSI14)
Sell
Level
48.67
ADX Line
Sell
Level
13.16
Williams %R
Neutral
Level
-46.0465
50-day SMA
Buy
Level
$0.37
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
101.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
Stock Forecast FAQ
In the current month, LPTX has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LPTX average analyst price target in the past 3 months is $3.00.
-
Where Will Leap Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Leap Therapeutics share price will rise to $3.00 per share over the next 12 months.
-
What Do Analysts Say About Leap Therapeutics?
Analysts are divided on their view about Leap Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Leap Therapeutics is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Leap Therapeutics's Price Target?
The price target for Leap Therapeutics over the next 1-year time period is forecast to be $3.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is LPTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Leap Therapeutics is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of LPTX?
You can purchase shares of Leap Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Leap Therapeutics shares.
-
What Is The Leap Therapeutics Share Price Today?
Leap Therapeutics was last trading at $0.37 per share. This represents the most recent stock quote for Leap Therapeutics. Yesterday, Leap Therapeutics closed at $0.38 per share.
-
How To Buy Leap Therapeutics Stock Online?
In order to purchase Leap Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Where Will Dell Stock Be in 5 Years?
So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
